Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark
Summary Background Hydroxyurea (HU) is the most commonly used cytoreductive treatment for patients with myeloproliferative neoplasms (MPN), but emerging data on pegylated interferon-alpha2 (pegIFNα) are encouraging. Optimal first-line treatment remains unclear. Methods DALIAH was a randomised, open-label, parallel-grou...